Phase II study of cisplatin, etoposide and paclitaxel in locally advanced or metastatic adenocarcinoma of gastric/gastroesophageal junction.

Simple item page
dc.contributor.authorSharma, Atulen_US
dc.contributor.authorRaina, Ven_US
dc.contributor.authorLokeshwar, Nen_US
dc.contributor.authorDeo, S V Sen_US
dc.contributor.authorShukla, N Ken_US
dc.contributor.authorMohanti, B Ken_US
dc.date.accessioned2009-05-28T06:30:45Z
dc.date.available2009-05-28T06:30:45Z
dc.date.issued2006-01-10en_US
dc.description.abstractBACKGROUND: Unresectable and metastatic gastric cancers carry a poor and dismal prognosis. Several phase II studies have identified effective anticancer drugs. AIMS: To evaluate safety and efficacy of low-dose cisplatin, etoposide and paclitaxel (CEP) based combination chemotherapy in locally advanced or metastatic adenocarcinoma of gastric/gastroesophageal junction. SETTING AND DESIGN: Prospective single-arm phase II study. MATERIALS AND METHODS: Thirty-three patients were enrolled onto this study, out of which, all but one received cisplatin 15 mg/m 2, etoposide 40 mg/m 2 and paclitaxel 50 mg/m 2, given on day 1 and 4 every week for three weeks in a 28-day cycle. Survival analysis was done using SPSS program. RESULTS: Median age of group was 56 years. Twenty-five were males. Twenty-nine had metastatic/inoperable disease and four patients had recurrent disease. Liver was the commonest metastatic site seen in 15 patients. With a median of 2 cycles per patient, a total of 76 cycles was administered. Grade III or IV toxicity were seen in 11 (35%) patients; diarrhea, 5 patients; vomiting, 3 patients; and neutropenia, 7 patients, 5 of whom also had fever). One patient died of neutropenic fever. Best responses, seen in 32 evaluable patients, were 2 CR (6.1%), 21 PR (63%) and 3 SD (9.2%). Four patients were considered operable after chemotherapy. With median follow-up of 11 months in surviving patients, median OS was 10 months and PFS was 8 months. Median OS was 13 months in responders versus 8 months in nonresponders (P =0.04). Seven patients survived> 12 months. CONCLUSION: Combination of low-dose CEP shows good clinical response and an acceptable toxicity profile in advanced or metastatic adenocarcinoma of gastric/gastroesophageal cancers. Whether addition of 5 FU or capecitabine adds to the benefit should be explored. This may be tested with other standard/conventional protocols in a randomized fashion.en_US
dc.description.affiliationDepartment of Medical Oncology, Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi, India. atul1@hotmail.comen_US
dc.identifier.citationSharma A, Raina V, Lokeshwar N, Deo SV, Shukla NK, Mohanti BK. Phase II study of cisplatin, etoposide and paclitaxel in locally advanced or metastatic adenocarcinoma of gastric/gastroesophageal junction. Indian Journal of Cancer. 2006 Jan-Mar; 43(1): 16-9en_US
dc.identifier.urihttps://imsear.searo.who.int/handle/123456789/49953
dc.language.isoengen_US
dc.source.urihttps://www.indianjcancer.comen_US
dc.subject.meshAdenocarcinoma --drug therapyen_US
dc.subject.meshAdulten_US
dc.subject.meshAgeden_US
dc.subject.meshAntineoplastic Combined Chemotherapy Protocols --adverse effectsen_US
dc.subject.meshCisplatin --administration & dosageen_US
dc.subject.meshEsophagogastric Junction --drug effectsen_US
dc.subject.meshEtoposide --administration & dosageen_US
dc.subject.meshFemaleen_US
dc.subject.meshHumansen_US
dc.subject.meshMaleen_US
dc.subject.meshMiddle Ageden_US
dc.subject.meshNeoplasm Recurrence, Local --drug therapyen_US
dc.subject.meshPaclitaxel --administration & dosageen_US
dc.subject.meshProspective Studiesen_US
dc.subject.meshStomach Neoplasms --drug therapyen_US
dc.subject.meshSurvival Rateen_US
dc.titlePhase II study of cisplatin, etoposide and paclitaxel in locally advanced or metastatic adenocarcinoma of gastric/gastroesophageal junction.en_US
dc.typeClinical Trial, Phase IIen_US
dc.typeJournal Articleen_US
Files
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.79 KB
Format:
Plain Text
Description:
Download
Collections
Indian Journal of Cancer